Number of voting rights as of April 30, 2023
NICOX Nicox SA Société anonyme with a registered capital of € 50,156,698 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On May 3,...
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. Nicox S.A. is developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.
0.44 | |
0.44 | |
- | |
0.44 | |
0.44 | |
0.44-0.64 | |
27 783 K | |
63 144 K | |
3 574 K | |
-0.1873 | |
0.853 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
NICOX Nicox SA Société anonyme with a registered capital of € 50,156,698 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On May 3,...
NICOX Press Release Nicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China Nicox’spartner, Ocumension Therapeutics, announced on April ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: